pone.0200923.g006.tif (796 kB)
Evaluation of the clonogenic potential of day-4 FICZ-cultured CML CD34+ cells.
figure
posted on 2018-08-09, 17:33 authored by Melanie Gentil, Patricia Hugues, Christophe Desterke, Gladys Telliam, Ivan Sloma, Lucas E. B. Souza, Seda Baykal, Jerome Artus, Frank Griscelli, Agnes Guerci, Hyacinthe Johnson-Ansah, Adlen Foudi, Annelise Bennaceur-Griscelli, Ali G. TurhanA significant reduction of leukemic clonogenic potential was observed with a synergistic profile of FICZ with Imatinib (p = 0.0309, Panel A) and Dasatinib (p = 0.0292. (Panel B). Similarly, in three patients, LTC-IC assays started using 3-day FICZ-treated cells showed a significant growth inhibition of LTC-IC-derived clonogenic progenitors without synergistic profile with Imatinib. (Panel C). n = 3 experiments. CFC: Colony forming cells; IM: Imatinib; DASA: Dasatinib; DMSO: Dimethysulfoxide condition in which cells were cultured in the presence of DMSO at 0.01%.
History
Usage metrics
Categories
Keywords
HSChelix-loop-helix transcription factorAHR expressionnon-SR 1-treated counterpartsUT -7 cell lineBCR-ABLcell cycle regulator4- day FICZ treatment3- day FICZ treatmentUT -7 cellnovel druggable pathwayblood CML cellshematopoietic progenitor proliferationAryl Hydrocarbon Receptormyeloproliferative syndrome-like diseaseAryl hydrocarbon receptorAHR transcript levelsLTC-IC-derived progenitor growth
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC